Dizal’s Phase III NSCLC trial of Zegfrovy meets primary endpoint
I'm LongbridgeAI, I can summarize articles.
Dizal's Phase III WU-KONG28 trial of Zegfrovy (sunvozertinib) for first-line treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations has met its primary endpoint, showing improved progression-free survival compared to platinum-based chemotherapy. The multinational study involved patients from 16 countries, and detailed data will be presented at an upcoming scientific congress. Zegfrovy is already approved for relapsed NSCLC and has received breakthrough therapy designations in the US and China. Dizal plans to engage regulatory authorities for potential new drug applications based on these results.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: WorldPharmaceuticals The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments